Entera Bio Form 3 / Gregory Burshtein ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Burshtein Gregory

(Last)

(First)

(Middle)

KIRYAT HADASSAH, MINRAV BUILDING,

FIFTH FLOOR

(Street)

JERUSALEM

9112002

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/28/2024

3. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief of R&D

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, par value NIS 0.0000769 per share	75,126⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	01/17/2029	Ordinary Shares, par value NIS 0.0000769 per share	20,000	3.97	D
Stock Option (right to buy)	⁽³⁾	03/16/2030	Ordinary Shares, par value NIS 0.0000769 per share	18,900	2.14	D
Stock Option (right to buy)	⁽⁴⁾	04/07/2031	Ordinary Shares, par value NIS 0.0000769 per share	51,000	3.61	D
Stock Option (right to buy)	⁽⁵⁾	04/28/2032	Ordinary Shares, par value NIS 0.0000769 per share	45,000	2.57	D
Stock Option (right to buy)	⁽⁶⁾	03/24/2033	Ordinary Shares, par value NIS 0.0000769 per share	65,000	0.795	D
Stock Option (right to buy)	⁽⁷⁾	04/19/2034	Ordinary Shares, par value NIS 0.0000769 per share	150,000	1.99	D

Explanation of Responses:

1. Includes a grant of 25,126 stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

2. The options vest over a four-year period that commenced on January 17, 2019, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

3. The options vest over a four-year period that commenced on March 16, 2020, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

4. The options vest over a four-year period that commenced on April 7, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

5. The options vest over a four-year period that commenced on April 28, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

6. The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

7. The options vest over a three-year period that commenced on April 19, 2024, with 33% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Remarks:

See Exhibit 24.1 - Power of Attorney

	/s/ Dana Yaacov-Garbeli, Attorney-in-fact	06/07/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Entera Bio (ENTX) Form 3Entera Bio / Gregory Burshtein ownership change